MedMira Inc. (MMIRF)
USD 0.02
(-70.43%)
USD 0.02
(-70.43%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.24 Million CAD | 32.09% |
| 2022 | 1.57 Million CAD | -8.29% |
| 2021 | 1.71 Million CAD | -8.36% |
| 2020 | 1.87 Million CAD | 8.9% |
| 2019 | 1.71 Million CAD | -25.29% |
| 2018 | 2.3 Million CAD | -11.87% |
| 2017 | 2.61 Million CAD | -52.5% |
| 2016 | 5.49 Million CAD | 50.56% |
| 2015 | 3.65 Million CAD | -15.92% |
| 2014 | 4.34 Million CAD | 55.34% |
| 2013 | 2.79 Million CAD | 1.5% |
| 2012 | 2.75 Million CAD | 21.19% |
| 2011 | 2.27 Million CAD | -26.02% |
| 2010 | 3.07 Million CAD | -0.38% |
| 2009 | 3.08 Million CAD | -20.2% |
| 2008 | 3.86 Million CAD | -11.55% |
| 2007 | 4.36 Million CAD | -33.99% |
| 2006 | 6.61 Million CAD | 19.63% |
| 2005 | 5.53 Million CAD | 15.77% |
| 2004 | 4.77 Million CAD | 0.9% |
| 2003 | 4.73 Million CAD | -0.88% |
| 2002 | 4.77 Million CAD | -29.0% |
| 2001 | 6.73 Million CAD | 100.53% |
| 2000 | 3.35 Million CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 461.7 Thousand CAD | 18.62% |
| 2024 Q2 | 386.36 Thousand CAD | -42.22% |
| 2024 Q1 | 668.72 Thousand CAD | 35.06% |
| 2023 Q1 | 596.15 Thousand CAD | 54.1% |
| 2023 FY | 2.07 Million CAD | 32.09% |
| 2023 Q2 | 459.74 Thousand CAD | -22.88% |
| 2023 Q3 | 527.49 Thousand CAD | 14.74% |
| 2023 Q4 | 495.12 Thousand CAD | -6.14% |
| 2022 Q4 | 386.85 Thousand CAD | -1.44% |
| 2022 Q3 | 392.48 Thousand CAD | -11.84% |
| 2022 FY | 1.57 Million CAD | -8.29% |
| 2022 Q1 | 349.02 Thousand CAD | -31.17% |
| 2022 Q2 | 445.2 Thousand CAD | 27.56% |
| 2021 Q3 | 233.3 Thousand CAD | -53.01% |
| 2021 Q1 | 478.92 Thousand CAD | 18.93% |
| 2021 Q2 | 496.53 Thousand CAD | 3.68% |
| 2021 FY | 1.71 Million CAD | -8.36% |
| 2021 Q4 | 507.09 Thousand CAD | 117.36% |
| 2020 Q1 | 354.99 Thousand CAD | -9.15% |
| 2020 Q3 | 602.99 Thousand CAD | 17.83% |
| 2020 Q2 | 511.76 Thousand CAD | 44.16% |
| 2020 FY | 1.87 Million CAD | 8.9% |
| 2020 Q4 | 402.68 Thousand CAD | -33.22% |
| 2019 FY | 1.71 Million CAD | -25.29% |
| 2019 Q1 | 421.71 Thousand CAD | -9.98% |
| 2019 Q2 | 477.71 Thousand CAD | 13.28% |
| 2019 Q3 | 429.2 Thousand CAD | -10.15% |
| 2019 Q4 | 390.75 Thousand CAD | -8.96% |
| 2018 Q1 | 579.86 Thousand CAD | 20.74% |
| 2018 FY | 2.3 Million CAD | -11.87% |
| 2018 Q4 | 468.44 Thousand CAD | -18.06% |
| 2018 Q3 | 571.66 Thousand CAD | -16.11% |
| 2018 Q2 | 681.44 Thousand CAD | 17.52% |
| 2017 Q2 | 562.52 Thousand CAD | -31.99% |
| 2017 FY | 2.61 Million CAD | -52.5% |
| 2017 Q4 | 480.25 Thousand CAD | -35.24% |
| 2017 Q3 | 741.6 Thousand CAD | 31.84% |
| 2017 Q1 | 827.08 Thousand CAD | -57.5% |
| 2016 Q1 | 1.29 Million CAD | 136.41% |
| 2016 FY | 5.49 Million CAD | 50.56% |
| 2016 Q2 | 1.05 Million CAD | -18.85% |
| 2016 Q3 | 1.2 Million CAD | 14.58% |
| 2016 Q4 | 1.94 Million CAD | 61.54% |
| 2015 Q4 | 548.07 Thousand CAD | -39.39% |
| 2015 Q3 | 904.21 Thousand CAD | -28.27% |
| 2015 FY | 3.65 Million CAD | -15.92% |
| 2015 Q2 | 1.26 Million CAD | 34.26% |
| 2015 Q1 | 938.92 Thousand CAD | -10.12% |
| 2014 Q4 | 1.04 Million CAD | -13.88% |
| 2014 FY | 4.34 Million CAD | 55.34% |
| 2014 Q3 | 1.21 Million CAD | -10.71% |
| 2014 Q1 | 727.38 Thousand CAD | 10.29% |
| 2014 Q2 | 1.35 Million CAD | 86.76% |
| 2013 Q4 | 659.53 Thousand CAD | -15.59% |
| 2013 Q2 | 714.63 Thousand CAD | 11.55% |
| 2013 Q1 | 640.61 Thousand CAD | -9.4% |
| 2013 Q3 | 781.36 Thousand CAD | 9.34% |
| 2013 FY | 2.79 Million CAD | 1.5% |
| 2012 FY | 2.75 Million CAD | 21.19% |
| 2012 Q1 | 682.75 Thousand CAD | 38.84% |
| 2012 Q2 | 1.24 Million CAD | 82.57% |
| 2012 Q4 | 707.07 Thousand CAD | 4.09% |
| 2012 Q3 | 679.3 Thousand CAD | -45.5% |
| 2011 Q4 | 491.74 Thousand CAD | -8.05% |
| 2011 FY | 2.27 Million CAD | -26.02% |
| 2011 Q2 | 710.84 Thousand CAD | 32.7% |
| 2011 Q1 | 535.66 Thousand CAD | -31.42% |
| 2011 Q3 | 534.81 Thousand CAD | -24.76% |
| 2010 FY | 3.07 Million CAD | -0.38% |
| 2010 Q4 | 781.12 Thousand CAD | 12.53% |
| 2010 Q3 | 694.16 Thousand CAD | -19.0% |
| 2010 Q2 | 857.03 Thousand CAD | 15.81% |
| 2010 Q1 | 740 Thousand CAD | -10.54% |
| 2009 Q3 | 672.01 Thousand CAD | -15.85% |
| 2009 Q2 | 798.56 Thousand CAD | 1.56% |
| 2009 Q1 | 786.32 Thousand CAD | -31.73% |
| 2009 FY | 3.08 Million CAD | -20.2% |
| 2009 Q4 | 827.14 Thousand CAD | 23.09% |
| 2008 Q1 | 805.62 Thousand CAD | -10.87% |
| 2008 FY | 3.86 Million CAD | -11.55% |
| 2008 Q4 | 1.15 Million CAD | 38.68% |
| 2008 Q3 | 830.47 Thousand CAD | -8.12% |
| 2008 Q2 | 903.91 Thousand CAD | 12.2% |
| 2007 Q4 | 903.84 Thousand CAD | 10.65% |
| 2007 Q2 | 1.32 Million CAD | -0.26% |
| 2007 FY | 4.36 Million CAD | -33.99% |
| 2007 Q3 | 816.86 Thousand CAD | -38.24% |
| 2007 Q1 | 1.32 Million CAD | -34.73% |
| 2006 Q3 | 1.77 Million CAD | 32.68% |
| 2006 Q4 | 2.03 Million CAD | 14.46% |
| 2006 FY | 6.61 Million CAD | 19.63% |
| 2006 Q1 | 1.47 Million CAD | -0.66% |
| 2006 Q2 | 1.33 Million CAD | -9.29% |
| 2005 Q1 | 1.27 Million CAD | 27.21% |
| 2005 Q2 | 1.48 Million CAD | 16.03% |
| 2005 Q3 | 1.28 Million CAD | -13.02% |
| 2005 Q4 | 1.48 Million CAD | 15.15% |
| 2005 FY | 5.53 Million CAD | 15.77% |
| 2004 Q2 | 1.23 Million CAD | 2.22% |
| 2004 Q4 | 1 Million CAD | -24.9% |
| 2004 FY | 4.77 Million CAD | 0.9% |
| 2004 Q1 | 1.2 Million CAD | -12.18% |
| 2004 Q3 | 1.33 Million CAD | 8.49% |
| 2003 Q2 | 1.04 Million CAD | 10.01% |
| 2003 Q4 | 1.37 Million CAD | 0.46% |
| 2003 Q3 | 1.36 Million CAD | 30.61% |
| 2003 FY | 4.73 Million CAD | -0.88% |
| 2003 Q1 | 951.2 Thousand CAD | -42.34% |
| 2002 Q2 | 864.39 Thousand CAD | -26.55% |
| 2002 Q1 | 1.17 Million CAD | 0.0% |
| 2002 FY | 4.77 Million CAD | -29.0% |
| 2002 Q3 | 1.08 Million CAD | 25.89% |
| 2002 Q4 | 1.64 Million CAD | 51.61% |
| 2001 FY | 6.73 Million CAD | 100.53% |
| 2000 FY | 3.35 Million CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 10.86 Million USD | 79.344% |
| Skye Bioscience, Inc. | 13.54 Million USD | 83.431% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 93.975% |
| Nascent Biotech, Inc. | 2.22 Million USD | -0.665% |
| Qrons Inc. | 643.67 Thousand USD | -248.731% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -440.268% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 55.48% |
| BioStem Technologies, Inc. | 22.97 Million USD | 90.23% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -143.062% |
| CSL Limited | 3.44 Billion USD | 99.935% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 96.092% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 92.404% |
| Rebus Holdings, Inc. | 664 Thousand USD | -238.057% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -68.088% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -476.205% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 85.98% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 97.413% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 54.357% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -757.653% |
| SQZ Biotechnologies Company | 85.61 Million USD | 97.378% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 23.027% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -49.457% |
| Mesoblast Limited | 5.9 Million USD | 61.967% |
| Marizyme, Inc. | 19.23 Million USD | 88.333% |
| Genus plc | 147.7 Million USD | 98.48% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 74.432% |
| Pharming Group N.V. | 225.49 Million USD | 99.005% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -9.567% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -67.322% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 73.082% |
| ContraFect Corporation | 56.88 Million USD | 96.054% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 49.084% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -51.797% |
| IMV Inc. | 37.7 Million USD | 94.047% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 19.555% |
| MultiCell Technologies, Inc. | 567.42 USD | -395497.617% |
| ONE Bio Corp. | 6.44 Million USD | 65.165% |
| Accustem Sciences Inc. | 3.74 Million USD | 40.084% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 97.388% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -321.966% |
| Q BioMed Inc. | 3.43 Million USD | 34.683% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 90.918% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 14.57% |
| Biomind Labs Inc. | 994.18 Thousand USD | -125.784% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 97.74% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -27.563% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 66.587% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -20.4% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 9078.8% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -22.321% |
| GB Sciences, Inc. | 1.42 Million USD | -58.021% |
| Alpha Cognition Inc. | 9.7 Million USD | 76.872% |
| HST Global, Inc. | 140.9 Thousand USD | -1493.037% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -99.545% |
| Halberd Corporation | 74.84 Thousand USD | -2899.252% |
| Enzolytics Inc. | 2.17 Million USD | -2.991% |
| Agentix Corp. | 1.37 Million USD | -63.637% |
| Resverlogix Corp. | 12.71 Million USD | 82.342% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 38.513% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.854% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -115.01% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 6.663% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -42.128% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 34.076% |
| AVAX Technologies, Inc. | 7.31 Million USD | 69.294% |
| Zenith Capital Corp. | 8.94 Million USD | 74.9% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.728% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -12785.024% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 8.578% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1208.794% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -16.856% |
| Kadimastem Ltd | 2.41 Million USD | 6.863% |
| Helix BioMedix, Inc. | 1.97 Million USD | -13.827% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1136.852% |
| LadRx Corporation | 3.81 Million USD | 41.112% |
| Cell Source, Inc. | 4.32 Million USD | 48.104% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -143.062% |
| NovAccess Global Inc. | 2.46 Million USD | 9.002% |
| Affymax, Inc. | 39.38 Million USD | 94.301% |
| Itoco Inc. | 919.14 Thousand USD | -144.217% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 47.039% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -100.599% |
| Mobile Lads Corp. | 554.54 Thousand USD | -304.782% |
| CytoDyn Inc. | 18.05 Million USD | 87.569% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -8818.511% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -919.957% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -58.101% |
| SYBLEU INC | 160.87 Thousand USD | -1295.298% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -23.585% |
| International Stem Cell Corporation | 5.27 Million USD | 57.414% |
| Bioxytran, Inc. | 3.82 Million USD | 41.24% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -4164.086% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -10934.262% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 93.81% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -38.733% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -205.055% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 27.846% |
| Neutra Corp. | 243.82 Thousand USD | -820.634% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 87.142% |
| PureTech Health plc | 144.59 Million USD | 98.448% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 89.045% |
| IXICO plc | 4.7 Million USD | 52.311% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 74.483% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.094% |
| CSL Limited | 3.89 Billion USD | 99.942% |
| Cellectis S.A. | 97.32 Million USD | 97.693% |